‘An Arm and a Leg’: Need an Expensive Drug? Here’s What You Need to Know
Even a personal finance expert can get stuck with a huge unexpected bill for a drug. Listen up for what you need to know about "copay accumulators."
The independent source for health policy research, polling, and news.
1,181 - 1,200 of 3,877 Results
Even a personal finance expert can get stuck with a huge unexpected bill for a drug. Listen up for what you need to know about "copay accumulators."
KHN senior correspondents Jenny Gold and Anna Maria Barry-Jester joined KVPR’s Kathleen Schock on “Valley Edition” to discuss their investigation into the abrupt closure of one of California’s largest chain of pain clinics — and the patients left behind.
The Biden administration’s request for billions more in funding to fight covid-19 hit a snag on Capitol Hill this week, as Democrats objected to Republican demands that money allocated to states but not yet spent be reclaimed. Meanwhile, the big annual spending bill about to cross the finish line addresses other health policy changes, such as giving the FDA authority to regulate “synthetic” nicotine. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Cohrs of Stat, and Jessie Hellmann of Modern Healthcare join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
U.S. and global drug manufacturers invested in Russia’s sizable pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion. Not everyone agrees.
Like others in academia or government who’ve served as public health advisers during the pandemic, Dr. Michael Mina traded his university role for a commercial venture. He recently took a top job at eMed, a startup that charges a premium price for monitoring at-home covid tests. Can experts do well by trying to do good?
The president used broad language to say that Americans no longer needed to worry about surprise bills, but there are exceptions to the new law that could cost unsuspecting consumers.
A new investment fund launched by one of the few Black venture capitalists in health care is focused on backing Black entrepreneurs. And the investors include some of the biggest names in for-profit health care.
KHN gives readers a chance to comment on a recent batch of stories.
The insurance company said that the birth of the Bull family’s twins was not an emergency and that NICU care was “not medically necessary.” The family’s experience with a huge bill sent to collections happened in 2020, but it exposes a hole in the new No Surprises law that took effect Jan. 1.
In May 2021, Lags Medical Centers, one of California’s largest chains of pain clinics, abruptly closed its doors amid a cloaked state investigation. Nine months later, patients are still in the dark about what happened with their care and to their bodies.
As the pandemic wanes, for now, the ever-rising cost of health care is again taking center stage. Meanwhile, a year into the Biden administration, the FDA finally has a Senate-confirmed commissioner, Dr. Robert Califf. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Hannah Wesolowski of the National Alliance on Mental Illness, about how the pandemic has worsened the nation’s mental health crisis and what can be done about it.
An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.
Dr. Mai Pham left her corporate career to spark change in a system that is failing millions of Americans with autism and other intellectual and developmental disabilities.
State medical boards have an obligation to investigate complaints about doctors, including those who may spread false information about medical care. But in Florida, Tennessee, and other states, lawmakers are moving to protect physicians using unproven covid treatments or spreading misinformation.
Congress is set to start its once-every-five-years review of the law that authorizes user fees to finance the hiring of personnel to speed the FDA review of drugs. The periodic renewals of “PDUFA” also give lawmakers a chance to make other changes to the agency at the hub of the pandemic. Meanwhile, the FDA could also find itself at the center of the abortion debate and a controversial new medication to treat Alzheimer’s disease. Anna Edney of Bloomberg News, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more.
Among the 764 hospitals hit with a 1% reduction in Medicare payments this year for having high numbers of patient infections and avoidable complications are more than three dozen that Medicare also ranks as among the best in the country.
Investigators allege a Texas company that arranges spine surgery and other medical care for people injured in car crashes accepted bribes in violation of 1960s-era racketeering law.
A hospital in Wisconsin sued to keep seven employees from taking jobs with a competitor. A health system in South Dakota is offering nurses $40,000 signing bonuses. Facilities with fewer resources are finding it difficult or impossible to compete for health care workers.
The backroom deal with politically connected Kaiser Permanente, which infuriated other Medi-Cal health plans, allows the health care giant to continue selecting the enrollees it wants.
Home health and hospice agencies are experiencing extreme worker shortages, which means they can’t provide services to all the patients seeking care.
© 2026 KFF